To explore the role of risk factors associated with T2DM in this context, we adjusted for duration of T2DM, history of insulin treatment, insulin secretagogues or other anti-diabetic medications, hypoglycemia episodes, fasting serum insulin and fasting glucose in model 3. This evidence concerns the gene INS and Hypoglycemia.